Personalis outlines 170% clinical test volume growth target for 2026 as reimbursement and MRD strategy accelerate [Seeking Alpha]
Personalis, Inc. (PSNL)
Last personalis, inc. earnings: 3/25 04:01 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
Chris Hall, President and CEO, highlighted, "2025 was the year we validated our winning MRD strategy. 2026 is the year we expect to scale. Physicians increasingly trust our NeXT Personal test. Our Clinical volumes are building, and Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market. Subscribe to Stock Ideas Sign Up Quick Insights Personalis claims leadership in ultrasensitive MRD testing, supported by the NeXT Personal test's detection capabilities at one part per million, strong growth in clinical volumes, new Medicare coverage decisions, and an expanding sales force. Management projects total 2026 revenue of $78-$80 million, anticipates 43,000-45,000 clinical test volumes (170% growth), and expects strategic revenue to grow driven by quadrupling in clinical volumes and expanded Medicare coverage for breast and lung cancer surveillance. Main risks include continued margin compression due to unreimbur
Show less
Read more
Impact Snapshot
Event Time:
PSNL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSNL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSNL alerts
High impacting Personalis, Inc. news events
Weekly update
A roundup of the hottest topics
PSNL
News
- Personalis (PSNL) had its price target lowered by Morgan Stanley from $11.00 to $10.00. They now have an "equal weight" rating on the stock.MarketBeat
- Personalis (PSNL) had its price target raised by Needham & Company LLC from $10.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Personalis Inc (PSNL) Q4 2025 Earnings Call Highlights: Robust Clinical Growth Amidst Revenue ... [Yahoo! Finance]Yahoo! Finance
- Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Personalis GAAP EPS of -$0.26 beats by $0.03, revenue of $17.35M beats by $0.23M [Seeking Alpha]Seeking Alpha
PSNL
Earnings
- 2/26/26 - Beat
PSNL
Sec Filings
- 2/26/26 - Form S-8
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- PSNL's page on the SEC website